Browsing by Author "Tanriverdi, Ozgur"
Now showing items 1-5 of 5
-
Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less
Ozaslan, Ersin; Karaca, Halit; Koca, Sinan; Sevinc, Alper; Hacioglu, Bekir; Ozkan, Metin; Ozcelik, Melike; Duran, Ayse O.; Hacibekiroglu, Ilhan; Yildiz, Yasar; Tanriverdi, Ozgur; Menekse, Serkan; Aksoy, Asude; Bozkurt, Oktay; Urvay, Semiha; Uysal, Mukremin; Demir, Hacer; Ciltas, Aydin; Dane, Faysal (LIPPINCOTT WILLIAMS & WILKINS, 2017)The objectives of this study were to compare progression-free survival (PFS) with somatostatin analog (SSA) versus chemotherapy (CTx) in first-line therapy and to determine the patient group in which these treatments were ... -
The mean platelet volume may predict the development of isolated bone metastases in patients with breast cancer: a retrospective study of the Young Researchers Committee of the Turkish Oncology Group (TOG)
Tanriverdi, Ozgur; Menekse, Serkan; Teker, Fatih; Oktay, Esin; Pilanci, Kezban Nur; Gunaldi, Meral; Kocar, Muharrem; Kacan, Turgut; Bahceci, Aykut; Avci, Nilufer; Akman, Tulay; Cokmert, Suna; Yesil-Cinkir, Havva; Yanmaz, Mustafa Teoman (ZERBINIS MEDICAL PUBL, 2016)Purpose: To determine the predictive value of the mean platelet volume (MPV) and the MPV/platelet count ratio on the development of isolated bone metastasis in patients with breast cancer. Methods: A total of 121 previously ... -
Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas
Cicin, Irfan; Ozatli, Tahsin; Turkmen, Esma; Ozturk, Turkan; Ozcelik, Melike; Cabuk, Devrim; Gokdurnali, Ayse; Balvan, Ozlem; Yildiz, Yasar; Seker, Metin; Ozdemir, Nuriye; Yapar, Burcu; Tanriverdi, Ozgur; Gunaydin, Yusuf; Menekse, Serkan; Oksuzoglu, Berna; Aksoy, Asude; Erdogan, Bulent; Hacioglu, M. Bekir; Arpaci, Erkan; Sevinc, Alper (GALENOS YAYINCILIK, 2016)Background: Prognostic factors and the standard treatment approach for gynaecological carcinosarcomas have not yet been clearly defined. Although carcinosarcomas are more aggressive than pure epithelial tumours, they are ... -
Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology)
Inal, Ali; Kodaz, Hilmi; Odabas, Hatice; Duran, Ayse Ocak; Seker, Mehmet Metin; Inanc, Mevlide; Elkiran, Emin Tamer; Gunaydin, Yusuf; Menekse, Serkan; Topcu, Turkan Ozturk; Urakci, Zuhat; Tastekin, Didem; Bilici, Mehmet; Cihan, Sener; Geredeli, Caglayan; Sezer, Emel; Uncu, Dogan; Arpaci, Erkan; Ozturk, Banu; Bal, Oznur; Uysal, Mukremin; Tanriverdi, Ozgur; Gumus, Mahmut; Ustaalioglu, Bala Basak Oven; Suner, Ali; Cokmert, Suna; Hacibekiroglu, Ilhan; Aydin, Kubra; Isikdogan, Abdurrahman (MEDKNOW PUBLICATIONS & MEDIA PVT LTD, 2018)Purpose: Almost half of all patients diagnosed with non-small cell lung cancer (NSCLC) have distant metastases at presentation. One-third of patients with NSCLC will have brain metastases. Without effective treatment, the ... -
XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology
Duran, Ayse Ocak; Karaca, Halit; Besiroglu, Mehmet; Bayoglu, Ibrahim Vedat; Menekse, Serkan; Yapici, Heves Surmeli; Yazilitas, Dogan; Bahceci, Aykut; Uysal, Mukremin; Sevinc, Alper; Hacibekiroglu, Ilhan; Aksoy, Asude; Tanriverdi, Ozgur; Arpaci, Erkan; Inanc, Mevlude; Dane, Faysal; Ozkan, Metin (ASIAN PACIFIC ORGANIZATION CANCER PREVENTION, 2014)Background: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC). The aim of this study was to compare ...
